Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

NPJ Breast Cancer · 2021 · PMC8159999 · PMID 34045483

Europe PMC DOI

hedged sentence

0.0577

closest p · 1.2× alpha

0.0577

boldest claim

The sentences

did not reach statistical significanceP = 0.0577so close (0.05 < p ≤ 0.1)

1e ), with a similar trend for CR, though it did not reach statistical significance ( P = 0.0577) (Fig. 1f ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.